Overview

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Collaborator:
Kyverna Therapeutics
Treatments:
Bendamustine Hydrochloride